Clinical trialsCompany release

Kailera plans global Phase 3 for oral ribupatide in 1H 2027 after FDA meeting

🇺🇸 Kailera Therapeutics, Inc. (KLRA) · Wed 04 Nov 2026

The US obesity drug developer reported Q3 results, saying it has $1.04bn in cash expected to fund operations into mid-2028.

Kailera Therapeutics said on 4 November 2026 that it has held an End-of-Phase 2 meeting with the US Food and Drug Administration for its oral GLP-1-based obesity candidate, ribupatide. The company intends to start a global Phase 3 programme in the first half of 2027.

The update came with the company's third-quarter results. Kailera said the Phase 2b and Phase 3 trials of injectable ribupatide, as well as its Phase 2 trial of safiglipron, are now fully enrolled.

The company also said the investigational new drug (IND) application for KAI-4729 is now active, which allows clinical work on that candidate to proceed in the US.

On finances, Kailera reported cash of $1.04 billion and said it expects this to fund operations into mid-2028. The summary provided does not give further detail on the design of the planned Phase 3 trials, their size or the outcome of the FDA discussions beyond the decision to proceed.

For context, an End-of-Phase 2 meeting is a standard step in US drug development in which a sponsor and the FDA discuss the data so far and the design of pivotal studies.

What it means for your team

  • Regulatory teams tracking the obesity field should expect a global Phase 3 start for oral ribupatide in 1H 2027, with trial details yet to be disclosed.
  • Full enrolment in the injectable ribupatide and safiglipron trials suggests further clinical data could emerge, though no readout dates were given.
  • Market-access analysts may note that the oral GLP-1 obesity space remains active, with Kailera's stated cash runway into mid-2028 covering the planned Phase 3 start.

Company's press release (SEC filing): Kailera Therapeutics, Inc. ↗

Article written by VigiEye from the official source (Kailera Therapeutics, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Clinical trials All →